The discovery of signaling networks that drive oncogenic processes has led to the development of targeted anticancer agents. The burden of pigmentary adverse events from these drugs is unknown.
To conduct a systematic review and meta-analysis of published clinical trials and determine the incidence and risk of development of targeted therapy–induced pigmentary changes.
A comprehensive search was conducted to identify studies reporting targeted therapy–induced pigmentary changes. The incidence and relative risk were calculated. Case reports and series were reviewed to understand clinical characteristics.
A total of 8052 patients from 36 clinical trials were included. The calculated overall incidences of targeted cancer therapy–induced all-grade pigmentary changes in the skin and hair were 17.7% (95% confidence interval [CI], 11.9-25.4) and 21.5% (95% CI, 14.9-30.1), respectively. The relative risk of all-grade pigmentary changes of skin and hair were 93.7 (95% CI, 5.86-1497.164) and 20.1 (95% CI, 8.35-48.248). Across 53 case reports/series (N = 75 patients), epidermal growth factor receptor and breakpoint cluster region–abelson inhibitors were the most common offending agents.
Potential under-reporting and variability in oncologists reporting these events.
There is a significant risk of development of pigmentary changes during treatment with targeted anticancer therapies. Appropriate counseling and management are critical to minimize psychosocial impairment and deterioration in quality of life.Le texte complet de cet article est disponible en PDF.
Key words : cabozantinib, depigmentation, dyspigmentation, hyperpigmentation, hypopigmentation, imatinib, ipilimumab, nivolumab, pazopanib, pembrolizumab, pigmentary, repigmentation, sorafenib, sunitinib, vitiligo
Abbreviations used : AE, Bcr-abl, BSA, CI, dpAE, RR, RCT
| Supported in part by the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P20 CA008748. Drs Lacouture and Belum are supported by the RJR Oncodermatology Fund. Funders and sponsors were not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
| Disclosure: Dr Wu has speaking arrangements with Novartis, Bayer-Onyx, Pfizer, and Mediavation. Dr Sibaud has a speaking, consultant, or advisory role with Roche, GlaxoSmithKline, Pierre Fabre, Merck, Bristol-Myers Squibb, Bayer, and Boehringer Ingelheim. Dr Lacouture has a speaking, consultant, or advisory role with Abbvie, Quintiles, Boehringer Ingelheim, AstraZeneca Pharmaceuticals, Legacy Healthcare, Foamix, Adgero Bio Pharmaceuticals, Janssen R&D, Novartis, and Novocure; in addition, he receives research grants from Berg and Bristol-Myers Squibb. Drs Dai and Belum have no conflicts of interest to declare.
| Reprints not available from the authors.